Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

TOKU-E Company Launches MycoRid™, a New Amphotericin B Solution Alternative

TOKU-E Company
Posted on: 21 Mar 18

TOKU-E Company is proud to launch the new antifungal solution, MycoRid™, for the cell culture industry to replace the traditional solubilised amphotericin B solution as the standard for fungal protection.

For many years, cell cultures have been treated with amphotericin B (Fungizone) to remove fungal infections or discarded when the infection was too difficult to eradicate. The preparation of Fungizone stock solutions are troublesome because amphotericin B is almost insoluble in water. To make amphotericin B more soluble, labs would use an amphotericin B formulation with deoxycholate as a solubilizer. Unfortunately, deoxycholate is an animal origin solubilizer and has a high level of cytotoxicity.

“TOKU-E has successfully developed a new formulation that uses a polyene antifungal agent similar to amphotericin B with a polysaccharide as the solubilizer. Both the polysaccharide and our polyene antifungal agent have shown lower levels of cytotoxicity in cell culture. We have been using this MycoRid™ formulation in our affiliated cell culture labs for quite a few years. I am very glad the management of TOKU-E has decided to share the MycoRid™ formulation with the cell culture industry,” said Q. Pan, TOKU-E Scientist.

When compared with solubilised amphotericin B (Fungizone), MycoRid™ is a more stable solution that can be stored at 4°C for up to 3 months, unlike amphotericin B solutions which are only stable for 2-3 weeks at similar temperatures. The longer shelf-life, improved solubility, low-cytotoxicity and increased potency make MycoRid™ a better alternative to traditional antifungal formulations for prevention and removal of fungal infections in cell cultures.

About TOKU-E Company

TOKU-E Company specializes in developing and manufacturing improved antibiotics and antimycotics for cell biology, plant biology, and microbiology. We are committed to bridging the application gap between pharmaceuticals and the antimicrobials utilized in bioscience research sectors through the effective use of proprietary fermentation and purification technologies. TOKU-E is the trusted source for unique and advanced antimicrobials around the world!

For more information about this and other products please visit our website at www.toku-e.com or email us at info@toku-e.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20180321005244/en/

Business Wire
www.businesswire.com

Last updated on: 21/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.